Advanz Pharma UK

Advanz Pharma UK 的所有者是 Advanz Pharma.

Advanz Pharma 是一家在股票代码 CXRXF (CA) 下上市的公司。

Advanz Pharma 在 2 个国家有直接业务。

查看带有其 6 名主要高管的组织结构图

Advanz Pharma UK 搜索最多的简介

• Susanna El Armale, Chief Corporate Development Officer
• David McNamara, Vice President of Sourcing, Procurement and Suppli...
• Melvin Ferry, Finance Director

创建提醒
跟踪 Advanz Pharma UK 的高管变动

Advanz Pharma 拥有 1,835 家竞争者，其中包括 Pfizer (美国(美洲))、Johnson & Johnson (美国(美洲)) 和 Sanofi (法国)。

Popular M&A news in 药店

• Grace Therapeutics将在Oct 24, 2024将其名称改为Grace Therapeutics。 (公布2024十月27号).
• Orasis Pharmaceuticals 刚刚宣布为 78 筹款数百万美元。 (公布2024十月21号).
• Lundbeck has announced the acquisition of Longboard Pharmaceuticals  (公布2024十月17号).

药店 行业的其他推荐联系人

• Sanofi 企业 Julie Van Ongevalle - Executive Vice President and Head of Consumer Healthcare
• Amneal Pharmaceuticals 企业 Paul Meister - Chairman of the Board
• Braeburn Pharmaceuticals 企业 Seth Harrison - Chairman and Director

了解更多有关药店行业的信息 >

Advanz Pharma UK 的最新新闻稿

• ADVANZ PHARMA Releases Environmental, Social & Governance (ESG) Report for 2023-2024 | ADVANZ PHARMA
• ADVANZ PHARMA’s response to European Commission revocation of conditional marketing authorisation for OCALIVA® in rare disease Primary Biliary Cholangitis (PBC) | ADVANZ PHARMA
• ADVANZ PHARMA secures temporary suspension of the European Commission decision on the OCALIVA® conditional marketing authorisation in Europe | ADVANZ PHARMA
• ADVANZ PHARMA and Enzene Enter an Exclusive Partnership for Biosimilar Development and Commercialisation | ADVANZ PHARMA
• ADVANZ PHARMA response to CHMP recommendation pertaining to EU conditional marketing authorization for OCALIVA® in rare disease Primary Biliary Cholangitis | ADVANZ PHARMA
• Alvotech and ADVANZ PHARMA Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe | ADVANZ PHARMA
• News | ADVANZ PHARMA
• ADVANZ PHARMA and Allecra Therapeutics announce approval in the European Union for the new antibiotic combination EXBLIFEP® (cefepime/enmetazobactam) for the treatment of severe infections | ADVANZ PHARMA
• ADVANZ PHARMA receives positive CHMP opinion for EXBLIFEP® (cefepime/enmetazobactam) | ADVANZ PHARMA
• ADVANZ PHARMA acquires global rights to Androcur® from Bayer | ADVANZ PHARMA
• View more press releases Close

关于 Advanz Pharma UK 的社交媒体

• Advanz Pharma UK 在 维基百科、谷歌新闻 和 雅虎财经
• Advanz Pharma UK 在 LinkedIn、叽叽喳喳 和 YouTube

通过电子邮件联系联系该企业高管，包括 Simon Tucker

致电Advanz Pharma UK，电话：+44 208...

查看组织结构图

Register to receive your alert

报告错误